Bio

Dai Yun graduated from China University of Political Science and Law in 2014 and has been working at Commerce & Finance Law Offices for eight years since then. Angela Dai specializes in overseas listing and bond offering, M&A and private equity financing for a wide range of companies in healthcare, pharmaceutical, medical devices and consumer goods industries. Angela Dai is involved in a number of high-profile IPO cases, including Shanghai Bio-heart Biological Technology Co., Ltd. （2185.HK), Beijing Airdoc Technology Co., Ltd.(2251.HK), Chaoju Eye Care Holdings Limited(2219.HK), Landsea Green Life Service Company Limited(1965.HK), Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(A+H Share IPO, 9989.HK), Peijia Medical Limited (9996.HK), EuroEyes International Eye Clinic Limited(1846.HK), Colour Life Services Group CO., Limited(1778.HK), Zhou Hei Ya International Holdings Company Limited(1458.HK), AK Medical Holdings Limited(1789.HK)IPO cases on the Hong Kong Stock Exchange and ECMOHO Limited’s IPO on the Nasdaq Stock Exchange. Angela Dai is also involved in a number of investment and financing projects, such as Greenwoods’s investment in Nanjing Yangzi Hospital, Ping An Trust’s investment in Aizhong Medical Group, a joint venture project between Ping An Capital and Rich Healthcare(HK.01526), Ping An Capital’s investment in an logistics platform, Hangzhou Dianwoda, KKR’s investments in Anhui Hetian Group, Guangdong Heping Hospital Management Group and Fareast Obstetrics and Gynecology Group, AK Medical’s investment in Beijing Libeier Bio-engineering Institute, GL Capital Group’s investments in Star Sports Medicine, Simoonrecord, Asia Pacific Medical Group, and JinXin Woman&Children Hospital, domestic and overseas restructuring projects invested by Technology Financial Group in Lvji Technology, Pagoda’s multi-round overseas investments in a large-scale fresh food retail platform, Li Ning’s acquisitions of Shenzhen Songri Dingsheng Building and Shanghai Changning Kaiqiao Culture Square, several rounds financing of Trinomab and Hainan Cancer Hospital's financing from China Life Private Equity. Angela Dai also led overseas bond issuance projects of Zhou Hei Ya International Holdings Company Limited and Credit China Holdings Limited. She has been providing perennial legal services to numerous companies for their daily operation including Viva China (8032.HK), AK Medical (1789.HK) and KKR’s portfolios.